Latest Breaking News On - Elran haber - Page 1 : vimarsana.com

LBP-immunotherapy could benefit oncology patients

Evogene : Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF...

Biomica CEO Set to Engage in Panel Discussion at 8th Annual European Microbiome Movement Summit

REHOVOT, Israel, Jan. 23, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. ,...

Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug

The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica's microbiome-based immuno-oncology drug, BMC128 REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ --...

Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024 - Evogene

Rehovot, Israel - - Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. , is gearing up for participation in...

Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024

REHOVOT, Israel , Dec. 21, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. , is...

Evogene Ltd. (NASDAQ:EVGN) Q3 2023 Earnings Call Transcript

Evogene Ltd. (NASDAQ:EVGN) Q3 2023 Earnings Call Transcript November 15, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to Evogene’s Third Quarter 2023 Results Conference Call. All participants are present in listen-only mode. Following management’s formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions] As a reminder, this conference […]

Startup Expands Trial For Bacteria-Based Cancer Treatment

An Israeli company that develops medical treatments using helpful bacteria is expanding the clinical trial for its cancer-fighting drug. 

Evogene's (EVGN) Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center

Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center

REHOVOT, Israel, Aug. 15, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. , has... -Today at 07:01 am- MarketScreener